TY - JOUR
T1 - Combined antibacterial effects of between meropenem and vancomycin, teicoplanin, linezolid, or arbekacin in methicillin-resistant Staphylococcus aureus
AU - Tsuchimochi, Noriko
AU - Uchida, Yujiro
AU - Nagasaki, Yoji
AU - Eriguchi, Yoshihiro
AU - Maehara, Yoriko
AU - Kadowaki, Masako
AU - Shimono, Nobuyuki
PY - 2007/9
Y1 - 2007/9
N2 - In vitro interaction between meropenem(MEPM) and vancomycin(VCM), teicoplanin(TEIC), linezolid (LZD) , or arbekacin(ABK) was studied using the checkerboard technique in 207 clinical isolates of methicillin-resistant Staphylococcus aureus(MRSA) (MIC of MEPM ≧32). Of 207 strains, synergistic or additive action was observed in all strains by combination of MEPM and VCM or TEIC. A combination of MEPM and LZD or ABK showed synergistic or additive 196 strains (94.7%) and 159 strains (76.8%). Antagonism was not observed in any combination of MEPM and VCM, TEIC, or LZD, but 22 strains (10.6%) exhibited antagonism in combination with MEPM and ABK. It is thus important to know both the susceptibility of anti-MRSA agents alone and the combined effects of agents.
AB - In vitro interaction between meropenem(MEPM) and vancomycin(VCM), teicoplanin(TEIC), linezolid (LZD) , or arbekacin(ABK) was studied using the checkerboard technique in 207 clinical isolates of methicillin-resistant Staphylococcus aureus(MRSA) (MIC of MEPM ≧32). Of 207 strains, synergistic or additive action was observed in all strains by combination of MEPM and VCM or TEIC. A combination of MEPM and LZD or ABK showed synergistic or additive 196 strains (94.7%) and 159 strains (76.8%). Antagonism was not observed in any combination of MEPM and VCM, TEIC, or LZD, but 22 strains (10.6%) exhibited antagonism in combination with MEPM and ABK. It is thus important to know both the susceptibility of anti-MRSA agents alone and the combined effects of agents.
UR - http://www.scopus.com/inward/record.url?scp=34948853322&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34948853322&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:34948853322
SN - 1340-7007
VL - 55
SP - 363
EP - 367
JO - Japanese Journal of Chemotherapy
JF - Japanese Journal of Chemotherapy
IS - 5
ER -